Organization · Venture Capital
ARCH Venture Partners
ARCH Venture Partners is a seed and early-stage venture capital firm based in Chicago and Seattle, specializing in investments in disruptive science and technology companies, particularly in life sciences and physical sciences.
Overview
What ARCH Venture Partners does
What ARCH Venture Partners is
ARCH Venture Partners is a seed and early-stage venture capital firm based in Chicago and Seattle, specializing in investments in disruptive science and technology companies, particularly in life sciences and physical sciences.
How it participates in the startup ecosystem
The current public profile supports funder and community and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1986
- Approximate age
- About 40 years
- Structured capabilities
- Funder · Community · Publisher
- Last reviewed
- March 27, 2026
Official channels
Find ARCH Venture Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
ARCH Venture Partners as a funder
Investment thesis
ARCH Venture Partners focuses on building transformative biotechnology companies at the concept stage, primarily in collaboration with leading scientists and researchers. The firm emphasizes revolutionary technologies that can significantly impact human health.
Focus narrative
ARCH Venture Partners invests in early-stage biotechnology companies, providing funding typically ranging from $500,000 to $5 million. The firm is particularly focused on transformative technologies in areas such as infectious disease, mental health, immunology, and genomic tools. ARCH operates globally and is recognized for its role in co-founding startups directly with university researchers, emphasizing a hands-on approach to building successful companies.
Value beyond capital
ARCH Venture Partners adds value to its portfolio companies through strategic partnerships, industry insights, and a robust network of relationships within the biotechnology sector. The firm is deeply involved in the development process, offering guidance and support to help companies navigate challenges and achieve their goals.
Terms and economics
- Typical check
- $500,000–$5,000,000
- Sweet spot
- $8,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 279
- Investments in the last 12 months
- 10
- Last recorded investment
- December 1, 2025
- Recorded notable exits
- Grail and Illumina
Portfolio context
Notable portfolio companies include: Illumina: A leader in genomic sequencing. Alnylam Pharmaceuticals: Focused on RNA interference therapeutics. Juno Therapeutics: Specializes in cell therapy for cancer. Agios Pharmaceuticals: Works on cancer metabolism and rare genetic diseases. Vir Biotechnology: Develops therapies for infectious diseases. Grail: Focused on early cancer detection (acquired). Twist Bioscience: Provides synthetic DNA solutions.
Capability profile
ARCH Venture Partners as a community
Community overview
ARCH Venture Partners is a venture capital firm founded over 30 years ago, based in Chicago, Illinois. The organization focuses on backing disruptive science companies, investing amounts ranging from $50,000 to hundreds of millions of dollars per company. ARCH is characterized by its contrarian approach, seeking revolutionary technologies that can significantly impact people's lives. The firm emphasizes a long-term view in building companies and utilizes an extensive network of partners to support the formation and growth of its portfolio companies.
Community focus
ARCH Venture Partners invests in companies that are based on groundbreaking scientific discoveries and technologies. The firm is particularly interested in sectors related to health and medicine, aiming to tackle significant medical challenges. ARCH takes a flexible approach to investment sizes and stages, focusing on long-term growth rather than quick returns.
Audience and fit
- Sectors
- Healthcare
- Regions
- North America
Community activity
Notable members
Notable portfolio companies include Agios Pharmaceuticals, Illumina, GRAIL, Receptos, and Vir Biotechnology.
Capability profile
ARCH Venture Partners as a publisher
Editorial focus
ARCH Venture Partners specializes in investing in early-stage biotechnology companies, particularly in the life sciences and physical sciences sectors. The firm emphasizes revolutionary technologies that can significantly impact human health, providing funding from $50,000 to hundreds of millions of dollars. ARCH seeks to back companies developing transformative technologies in areas such as infectious disease, mental health, immunology, and genomic tools.
Audience value
ARCH Venture Partners offers invaluable expertise, a strong network, and a commitment to building transformational companies in the life sciences sector.
Format and cadence
- Content formats
- blog
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Investors · Founders
- Sectors
- Biotech & Life Sciences
- Regions
- Global · North America
Flagship work and coverage
Flagship properties
ARCH Venture Partners publishes news updates and media coverage highlighting significant developments and achievements of the firm and its portfolio companies.
Notable coverage
ARCH is recognized for its contrarian investment approach and has been featured in various articles and press releases discussing its impact on the biotechnology sector.
Common questions
What to know about ARCH Venture Partners
Upseed classifies ARCH Venture Partners under the Venture Capital organization type. Its current public profile includes funder, community, and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.